Citigroup Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $266
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst David Lebovitz maintains a 'Buy' rating on Alnylam Pharmaceuticals and raises the price target from $265 to $266.
August 04, 2023 | 3:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Citigroup maintains a 'Buy' rating on Alnylam Pharmaceuticals and raises the price target from $265 to $266, which could potentially boost investor confidence.
The raised price target by Citigroup indicates a positive outlook for Alnylam Pharmaceuticals. This could potentially lead to increased investor confidence and a short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100